Firas B Badin, MD
Clinical Focus
Practice Locations
Education
University of Kentucky Medical Center
InternshipNewark Beth Israel Medical Center
ResidencyNewark Beth Israel Medical Center
Medical SchoolUniversity of Damascus School of Medicine
Board Certifications
American Board of Internal Medicine
-American Board of Internal Medicine
Hospital Affiliations
- Baptist Health Medical Group
- Baptist Health Lexington
- Baptist Health Richmond
Philosophy of Care
Research
-
Breast Cancer
EA1181: Preoperative THP and Postoperative HP in Patients Who Achieve a Pathologic Complete Response Part 1 Component of: The CompassHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in HER2-Positive Breast Cancer)
Trial Details -
Extensive-stage Small-cell Lung Cancer
EMERGE 402: Stage IV observational study for adult patients with metastatic SCLC
Trial Details -
Lung Cancer
A081801-Alchemist Sub-Study: This phase III ALCHEMIST trial compares the addition of pembrolizumab to usual chemotherapy versus usual chemotherapy for the treatment of stage IB, II, or IIIA non-small cell lung cancer that has been removed by surgery.
Trial Details -
Lung Cancer
Alliance A151216: ALCHEMIST - Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial
Trial Details -
Non-small Cell Lung Cancer
EF-36/Keynote: A pilot, single arm, open-label study of Tumor Treating Fields (TTFields, 150 kHz) concomitant with pembrolizumab for first line treatment of advanced or metastatic intrathoracic non-small cell lung cancer
Trial Details -
Non-small Cell Lung Cancer (NSCLC)
Pacific 9: A Phase III, double-blind, placebo-controlled, Randomized, Multicentre, International Study of Durvalumab Plus Oleclumab and Durvalumab Plus Monalizumab in Patients With Locally Advanced (Stage III), Unresectable Non-small Cell Lung Cancer (NSCLC) Who Have Not Progressed Following Definitive, Platinum-Based Concurrent Chemoradiation Therapy
Trial Details -
Non-small Cell Lung Cancer (NSCLC)
BeiGene A317-A1217-302: A Phase 3, Randomized, Double-Blind Study of BGB-A1217, an Anti-TIGIT Antibody, in Combination With Tislelizumab Compared to Pembrolizumab in Patients With Previously Untreated, or Metastatic Non-Small Cell Lung Cancer
Trial Details -
Non-small Cell Lung Cancer (NSCLC) (WIRB-22-0106)
Skyscraper: A Phase II/III, Randomized, Double Blind, Placebo-Controlled Study of Tiragolumab in Combination with Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab
Trial Details -
NSC Lung Cancer
Razor-Encore - A Randomized Prospective Trial of Adjuvant Chemotherapy in Patients With Completely Resected Stage I or IIA Non-Squamous Non-Small Cell Lung Cancer Identified as Intermediate or High Risk by a 14-Gene Prognostic Assay
Trial Details -
Previously Treated Non-Small Cell Lung Cancer
LungMAP: A Master Protocol to Evaluate Biomarker-Driven Therapies and Immunotherapies in Previously-Treated Non-Small Cell Lung Cancer (Lung-MAP Screening Study)
Trial Details -
Small Cell Lung Carcinoma
MK3475-B98: A Phase 1b/2 Study to Evaluate Efficacy and Safety of Pembrolizumab in Combination w Investigational Agents for Treatment of Participants With PD-1/L1- refractory Extensive-Stage Small Cell Lung Cancer in Need of Second-Line Therapy (Keynote-B
Trial Details